Search
Equine Botulinum Neurotoxin F Immune FAB2
go.drugbank.com/drugs/DB13901ApprovedEquine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F. It is intravenously administered for the treat...
Mixtures: BatFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnSome clinical data has suggested that the clinically recommended dose of 250mg was too low. … It is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersBerotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigational[L26661] Berotralstat was approved by the European Commission on April 30, 2021 [L41965] and by Health Canada on June 06, 2022. … [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older.
Synonyms: 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide, (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochlorideCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsOlodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalActivation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). … Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production.
Mixtures: SPIOLTO RESPIMAT 2.5 MCG/2.5 MCG INHALASYON ÇÖZELTISI,1 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesGS030-DP
go.drugbank.com/drugs/DB17847InvestigationalIt is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigational[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 InhibitorsSN-38
go.drugbank.com/drugs/DB05482Investigational7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan [DB00762], a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer … SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negative Breast Cancer, among others.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsBalsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approvedas safe (GRAS). … Balsam of Peru has also presented several allergens such as cinnamic acid, [DB06770] and [DB02130].
Mixtures: DERIVERIN MERHEM, 25 GAnisindione
go.drugbank.com/drugs/DB01125Approvedwell as the anticoagulant proteins C and S, in the liver. … is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as
Neisseria meningitidis serogroup b nada protein antigen
go.drugbank.com/drugs/DB10785ApprovedInvestigationalMixtures: BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 10 ADET İĞNESİZ, BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET 2 İĞNELİ